Shanghai Shenqi Pharmaceutical Investment Management Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Feng Bin

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	12.9yrs
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

CEO

Feng Bin (49 yo)

12.9yrs

Permanencia

CN¥451,700

Compensación

Mr. Feng Bin is the Managing Director and Director of Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd. (formerly known as Shanghai Wingsung Investment Management Co., Ltd.) and served as its...

Shanghai Shenqi Pharmaceutical Investment Management Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., Annual General Meeting, May 20, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., Annual General Meeting, May 20, 2024

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.064 (vs CN¥0.015 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.023 (vs CN¥0.018 in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.04 (vs CN¥0.04 in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.039 (vs CN¥0.018 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.018 (vs CN¥0.04 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.04 in 1Q 2021)

Less than half of directors are independent

Now 20% undervalued

Third quarter 2021 earnings released: EPS CN¥0.018 (vs CN¥0.33 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.04 (vs CN¥0.038 in 2Q 2020)

Full year 2020 earnings released: CN¥0.64 loss per share (vs CN¥0.16 profit in FY 2019)

New 90-day low: US$0.41

New 90-day low: US$0.41

New 90-day low: US$0.51

Third quarter earnings released

New 90-day low: US$0.62

Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd. to Report Q3, 2020 Results on Oct 31, 2020

First half earnings released

New 90-day high - US$0.69

Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd. to Report First Half, 2020 Results on Aug 29, 2020

CEO

Permanencia

Compensación